This HTML5 document contains 137 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://dx.doi.org/10.1111/
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q51353951
rdf:type
wikibase:Item
schema:description
scienca artikolo 2012年學術文章 2012年學術文章 vědecký článek vitskapeleg artikkel artigo científico научна статия videnskabelig artikel teaduslik artikkel 2012年学术文章 vetenskaplig artikel מאמר מדעי artikel ilmiah vedecký článok 2012年学术文章 tieteellinen artikkeli scientific article published in October 2012 บทความทางวิทยาศาสตร์ wissenschaftlicher Artikel 2012年学术文章 artikulong pang-agham articol științific naučni članak 2012年學術文章 мақолаи илмӣ 2012年學術文章 2012年の論文 artigo científico article científic 2012年学术文章 2012年学术文章 scientific article published in October 2012 article scientific wetenschappelijk artikel 2012년 논문 scientific article published in October 2012 artículu científicu επιστημονικό άρθρο artículo científico publicado en 2012 2012年學術文章 artikull shkencor অক্টোবর ২০১২-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ bài báo khoa học научная статья bilimsel makale tudományos cikk article scientifique 2012 nî lūn-bûn სამეცნიერო სტატია artykuł naukowy vitenskapelig artikkel artigo científico наукова стаття, опублікована в жовтні 2012 2012年学术文章 научни чланак научни чланак articolo scientifico مقالة علمية نشرت في أكتوبر 2012
p:P577
wds:Q51353951-BF660AE1-0B71-4AF0-82B8-490AA1740009
wdt:P577
2012-10-01T00:00:00Z
p:P2860
wds:Q51353951-F9CD1F6E-96EC-403B-AFAA-CED8127A4F3F wds:Q51353951-FCE45A3D-D5C7-449C-A2CA-E32F11FE236A wds:Q51353951-EA68C368-DD4A-4CCC-AF05-D89E06BE7203 wds:Q51353951-443913B4-5176-46F1-9086-4F16FD579AB1 wds:Q51353951-22756DC7-54A0-41B9-B9FB-75C73059F015 wds:Q51353951-41B5BD82-958D-42C8-8ECE-69EB1964A639 wds:Q51353951-001DD57A-52C3-411E-B1B7-72DDAA146D15 wds:Q51353951-02BDD1B8-6272-4572-9EA4-4AE5D7895E4E wds:Q51353951-189055C5-D67A-4974-A4C9-FADA910EDB94 wds:Q51353951-1A4AC876-B5C8-42BA-AB2A-9495CB377A6F wds:Q51353951-C19B93D2-D549-426C-9235-C89D3AE90AF2 wds:Q51353951-CB3C2A3D-953A-4FD8-8575-90B7BE2B0C00 wds:Q51353951-B2FBF61F-2025-4529-A4B5-8D4FFD516084 wds:Q51353951-873CD8EB-A64E-4AF1-B1B8-71470F68DE99 wds:Q51353951-8C89D8A5-432B-49FD-960B-A58D106CDD85 wds:Q51353951-8EBBB8A2-06A8-4A8C-850C-13DA50688065 wds:Q51353951-9E488320-03EB-48F7-ADB0-60588B93F81F
wdt:P2860
wd:Q37364896 wd:Q34835217 wd:Q35818970 wd:Q47296454 wd:Q42165729 wd:Q34598940 wd:Q43054066 wd:Q46357275 wd:Q28263292 wd:Q28293505 wd:Q37527141 wd:Q51381364 wd:Q36108419 wd:Q44909518 wd:Q51381372 wd:Q43195702 wd:Q46344895
p:P2093
wds:Q51353951-FFCC64CF-7754-471F-8125-FB38AF8805F9 wds:Q51353951-B2AA1C5A-071F-4868-BB21-5930B72EE6C4 wds:Q51353951-75E90B6B-DAC9-472D-9344-728448226CF0 wds:Q51353951-36AA453E-9CBB-4513-8BD6-7B12E06046E3 wds:Q51353951-60748010-A5C3-48CB-A839-95AF2A6C5D60
wdt:P2093
A Chang F T Botros Z Milicevic G Garcia Soria R Bsharat
rdfs:label
Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study.
skos:prefLabel
Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study.
schema:name
Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study.
p:P50
wds:Q51353951-7A0991E1-E742-44DC-ABB3-9D60AA68CD2F
wdt:P50
wd:Q90148608
p:P1476
wds:Q51353951-81097ACC-FF14-4804-BDCC-AC32B3E0447A
wdt:P1476
Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study.
p:P304
wds:Q51353951-73863C73-9E15-43AC-98E8-0216DC0AA40A
wdt:P304
1260-1267
p:P31
wds:Q51353951-7EF45741-2C74-4A13-9078-D3C6CF8A048B
wdt:P31
wd:Q13442814
p:P921
wds:Q51353951-CC14E526-E1ED-4C5A-89BD-AAF1251C3E2F wds:Q51353951-F2A1873E-58C2-46C4-A433-94819ADB8B56 wds:Q51353951-BE3E5AC9-970C-4514-ABC4-C919A9CE3E39
wdt:P921
wd:Q3025883 wd:Q269829 wd:Q181600
p:P698
wds:Q51353951-C68B2B22-3FE6-465D-B42B-902407D52F1D
wdtn:P698
n12:22804250
wdt:P698
22804250
p:P1433
wds:Q51353951-52A3B4DD-CA5C-4731-B3A5-C81411D33091
wdt:P1433
wd:Q15758639
p:P433
wds:Q51353951-AB018952-F07A-448A-A710-A7EBA4080A15
p:P478
wds:Q51353951-E01420FD-C75F-4D6C-98C7-983E85CD84A6
wdt:P433
10
wdt:P478
29
p:P356
wds:Q51353951-323B05C6-B2CD-479D-B598-941FABB37A39
wdtn:P356
n8:J.1464-5491.2012.03745.X
wdt:P356
10.1111/J.1464-5491.2012.03745.X